Letromyl

Letrozole, the active ingredient in Letromyl, is a aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of hormone‑receptor positive breast cancer in postmenopausal women.

GNH USA supplies Letromyl as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letromyl, an aromatase inhibitor, is used in breast‑cancer treatment pathways that depend on estrogen suppression. - Hormone‑receptor positive breast cancer (postmenopausal): reduces tumor growth and recurrence. - Adjuvant therapy: helps prevent disease return after surgical removal of the tumour. - Neoadjuvant therapy: shrinks tumours before surgery to enable breast‑conserving procedures. - Metastatic disease: controls progression in advanced hormone‑sensitive breast cancer.

Letrozole may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching in knees, hips, or back. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Severe liver injury: jaundice, dark urine, elevated enzymes. - Bone fracture: increased risk due to reduced bone density. - Pulmonary embolism: sudden shortness of breath, chest pain. - Allergic reaction: rash, swelling, or anaphylaxis. - QT interval prolongation: potential cardiac arrhythmia. - Severe hypertension: markedly high blood pressure.

Before initiating Letromyl therapy, clinicians should consider several safety measures. - Monitor liver function: obtain baseline tests and repeat periodically. - Assess bone health: supplement calcium and vitamin D, consider bone‑density scanning. - Evaluate cardiovascular risk: check blood pressure and lipid profile. - Avoid use in pregnancy: drug is contraindicated for women who are or may become pregnant. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Tamoxifen: concurrent use may antagonize therapeutic effect. - Strong CYP3A4 inducers (e.g., rifampin): may reduce letrozole plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure and toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - Corticosteroids: may exacerbate bone loss. - Selective serotonin reuptake inhibitors: may increase risk of hyponatremia.